Endometriosis recurs after surgery because excision removes the lesions but does not address the upstream environment that selected for them in the first place. The lesions are the readout of a specific physiological state. That state includes a dysregulated gut microbiome whose beta-glucuronidase activity drives recirculation of estrogen metabolites that should have been excreted, a barrier failure that produces sustained low-grade systemic inflammation, mast cell infiltration of pelvic tissues that lowers the threshold for ectopic implantation and growth, mitochondrial dysfunction in both the endometriotic tissue and the surrounding host environment, and local iron-driven oxidative damage that compounds with each menstrual cycle. Surgery resolves the local lesion. It does not change the substrate that selected for it. Without addressing the substrate, the disease has the same conditions to redevelop, often in new locations. This pattern is what the literature documents as recurrence rates of 20 to 40 percent within five years of excision, even when the surgical work is performed by skilled excision specialists.

The clinical pattern that defines recurrent endometriosis

A patient presents with severe dysmenorrhea, often beginning shortly after menarche but typically dismissed for years as "bad periods." Pelvic pain extends beyond the menstrual window. Pain with intercourse develops. Bowel symptoms emerge, often misdiagnosed as IBS. Fatigue is severe and disproportionate to the visible illness. The patient sees three to seven physicians over six to ten years before receiving an endometriosis diagnosis. The diagnosis is confirmed by laparoscopy. Excision surgery is performed.

For some patients, surgery produces substantial and durable relief. For many, the relief is partial. For a substantial fraction, the symptoms return within months to a few years, often with new lesion locations identified at subsequent imaging or surgery. The recurrence is sometimes attributed to incomplete excision at the original surgery, sometimes to "aggressive disease," sometimes to inadequate hormonal suppression in the post-operative period. The patient is offered another surgery, often with the addition of continuous oral contraceptives, GnRH agonists (Lupron, Orilissa), or progestins (Visanne, Mirena IUD) to suppress the disease.

The medications reduce symptom severity in some patients. They produce significant side effects in many. They are not curative. The disease persists at the underlying tissue level even when symptoms are suppressed. When the medication is discontinued, recurrence is the rule rather than the exception. The standard treatment cycle becomes a sequence of surgeries interspersed with hormonal suppression, with diminishing returns on each cycle.

This pattern is well-documented in the gynecological literature. The five-year recurrence rate after excision is widely reported in the 20 to 40 percent range, with some studies reporting higher figures depending on definition and follow-up duration. Endometriosis is the leading cause of hysterectomy in women under 40 in the United States, and even hysterectomy with bilateral salpingo-oophorectomy does not consistently eliminate the disease. The literature documents persistent endometriotic lesions after complete removal of the ovaries, which is inconsistent with a purely hormonal model of the disease.

The standard explanation for these patterns involves a combination of genetic predisposition, retrograde menstruation, immune dysfunction, and hormonal sensitivity. Each component has supporting evidence. None of them, alone or together, predicts the specific recurrence patterns observed clinically. The framework is incomplete. The missing piece is the upstream physiological state that selects for the disease and that surgery does not address.

Why the standard endometriosis model produces variable results

The standard model of endometriosis pathogenesis rests on Sampson's hypothesis of retrograde menstruation: viable endometrial cells are deposited in the peritoneal cavity through retrograde flow through the fallopian tubes during menstruation, and these cells implant and grow ectopically. The treatment implications follow directly. Reduce the menstrual flow that produces the seeding (hormonal suppression). Remove the lesions that have already implanted (surgery). Suppress the hormonal environment that supports lesion growth (estrogen suppression, progestin therapy).

The data do not fully support this model. Retrograde menstruation occurs in approximately 90 percent of women but endometriosis develops in approximately 10 percent. The seeding cannot be the sufficient cause. Something about the recipient environment determines whether retrograde-deposited cells establish viable lesions. The standard model has names for this something (immune surveillance failure, hormonal milieu, peritoneal microenvironment), but it does not specify the mechanism in clinically actionable terms.

The mechanism the literature is increasingly converging on, particularly in research from 2022 onward, involves the gut microbiome and its influence on estrogen metabolism, immune function, and inflammatory tone. The Host Capacity Model framework names this convergence and integrates it with the broader systems-biology understanding of chronic illness. The recipient environment is not a vague immunologic state. It is a specific physiological substrate that can be characterized, measured, and addressed. The lesions are the readout. The substrate is the mechanism.

The Host Capacity Model reading of endometriosis

The Host Capacity Model is a systems-biology framework that approaches chronic illness from the layer of cellular bioenergetics, gut barrier integrity, microbial community function, and regulatory cofactor pools. The framework is described in full at biomelogic.net/host-capacity-model. In endometriosis, the framework points to five specific mechanisms that together determine whether retrograde-deposited cells establish viable disease.

Mechanism 1: The estrobolome and beta-glucuronidase

The estrobolome is the collection of gut microbial genes encoding enzymes that metabolize estrogens. The dominant relevant enzyme is beta-glucuronidase, produced primarily by members of the Bacteroidetes phylum and certain Clostridium species. Beta-glucuronidase deconjugates glucuronidated estrogen metabolites in the intestinal lumen, removing the chemical tag that marked them for fecal excretion. The deconjugated estrogens are then reabsorbed across the intestinal epithelium and re-enter enterohepatic circulation.

This is a normal physiological process at baseline activity. The hepatic conjugation and beta-glucuronidase deconjugation cycles operate as part of the enterohepatic system that regulates circulating estrogen. The problem in endometriosis is that beta-glucuronidase activity is often substantially elevated due to gut dysbiosis. The Clostridium and Bacteroides expansion that accompanies dysbiosis produces higher beta-glucuronidase activity. The result is increased deconjugation of estrogen metabolites, increased reabsorption, and increased circulating estrogen exposure independent of ovarian production.

Multiple studies have documented elevated beta-glucuronidase activity in stool and circulating estrogen metabolites in endometriosis patients compared to healthy controls. The elevation is not subtle. Some studies report two-fold to three-fold increases in beta-glucuronidase activity in symptomatic disease compared to asymptomatic controls. This is the gut-endometriosis link in its most directly measurable form.

The clinical consequence is that hormonal suppression of ovarian estrogen production addresses one source of estrogen exposure while leaving another untouched. The patient on continuous oral contraceptives may have suppressed ovarian estrogen but continue to be exposed to recycled estrogen metabolites from the enterohepatic circulation. The endometriotic lesions, which are exquisitely estrogen-sensitive, have an estrogen supply that the medication did not eliminate. This is one of the mechanisms behind the variable response to hormonal therapy in endometriosis.

The estrobolome research is an active and growing area. Recent reviews by Baker and colleagues, Plottel and Blaser, and others have characterized the mechanism in detail. The translation into clinical endometriosis care has lagged behind the research. The Host Capacity Model frames this gap explicitly.

Mechanism 2: Gut barrier failure and LPS-driven inflammation

Endometriotic lesions develop within an environment of sustained low-grade systemic inflammation. The inflammation is not produced primarily by the lesions themselves, although they do contribute. It is produced upstream, often by gut barrier dysfunction that allows bacterial products including lipopolysaccharide (LPS) to translocate from the intestinal lumen into systemic circulation.

LPS is a potent ligand for Toll-like receptor 4 (TLR4), expressed on macrophages, mast cells, and many other immune cells. Sustained low-grade LPS exposure produces sustained low-grade TLR4 activation, sustained low-grade NF-kB signaling, and sustained low-grade pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta). The systemic inflammatory tone that results is permissive for endometriotic lesion implantation and growth. The lesions arrive into an environment that is already inflamed, and the inflammation supports their establishment.

Khan and colleagues have documented elevated peritoneal LPS in endometriosis patients. The mechanism connects directly to the gut barrier failure described in the recurrent SIBO article. The same colonocyte bioenergetic failure that drives recurrent SIBO also weakens the barrier, allows LPS translocation, and contributes to the inflammatory milieu that endometriotic lesions need.

This is one of the reasons endometriosis and SIBO co-occur so frequently. Multiple studies have documented elevated rates of SIBO in endometriosis patients, with prevalence estimates ranging from 30 to 80 percent depending on the diagnostic criteria used. The co-occurrence is not coincidence. The two conditions share a common upstream lesion in the gut barrier.

Mechanism 3: Mast cell infiltration of endometriotic lesions

Endometriotic lesions are densely infiltrated by mast cells. The mast cell density in endometriotic tissue exceeds that in normal endometrium by several fold. The mast cells contribute substantially to the pain, inflammation, and progression of the disease. Tryptase, histamine, prostaglandins, and the mast cell-derived growth factors (NGF, VEGF) all contribute to lesion development and to the sensitization of pelvic nociceptors.

The relevant question is what drives the mast cell infiltration. The mast cells are responding to specific signals in the pelvic microenvironment. The signals include LPS arriving from gut translocation (per Mechanism 2), substance P released from sensitized nerve fibers, and locally produced cytokines from the inflammatory milieu. The mast cells are not the primary lesion. They are a downstream amplifier of an upstream inflammatory state.

This mechanism connects endometriosis to the four-pattern MCAS framework. Many endometriosis patients have features of Pattern A MCAS (barrier-driven) operating systemically while the same mechanism operates locally in pelvic tissues. Treating the endometriosis while leaving the mast cell driver untouched produces partial response. Addressing both produces more complete response.

The clinical implication is that mast cell stabilizers, including cromolyn, ketotifen, and quercetin, often provide meaningful symptomatic relief in endometriosis patients. The mainstream gynecological literature has not formalized this, but the clinical experience among practitioners working in the gut-endo overlap space documents the pattern consistently.

Mechanism 4: Mitochondrial dysfunction in endometriotic tissue

Endometriotic lesions show specific mitochondrial abnormalities compared to normal endometrium. The lesions have altered electron transport chain function, increased glycolytic shift, and elevated reactive oxygen species production. The mitochondrial dysfunction is not just a consequence of the lesion environment. It contributes to the lesion's persistence and aggressive behavior. Mitochondria are not passive bystanders. They are signaling organelles that influence apoptosis, immune signaling, and cellular fate decisions.

Several recent studies have documented these mitochondrial abnormalities. The shift toward aerobic glycolysis in endometriotic tissue parallels the Warburg effect seen in cancer biology, although endometriosis is not cancer. The shift allows lesions to proliferate even in marginal substrate conditions. It also produces lactate accumulation, which acidifies the local microenvironment and further sensitizes pain receptors.

The systemic mitochondrial story matters as well. Endometriosis patients frequently report fatigue disproportionate to their visible illness. The fatigue is consistent with the broader bioenergetic failure described in the article on why labs come back normal in chronic illness. The CD38-NAD+-SIRT3 cascade operates in endometriosis as it does in other chronic inflammatory states. The fatigue is not a separate problem. It is the systemic readout of the same bioenergetic compromise that allows the local disease to persist.

Mechanism 5: Iron-driven oxidative damage in pelvic tissues

Endometriotic lesions undergo cyclic bleeding with each menstrual cycle. The blood is contained within the pelvic environment, where iron is released as the heme is metabolized. The released iron, particularly the free iron that is not properly chelated by ferritin or transferrin, drives Fenton chemistry: the reaction of iron with hydrogen peroxide produces hydroxyl radicals, which are among the most damaging reactive oxygen species in biology.

The cumulative iron-driven oxidative damage in pelvic tissues over decades of cyclic bleeding produces tissue changes that support disease progression. Adjacent normal tissue becomes inflamed and fibrotic. Adhesions form. The peritoneal environment becomes increasingly hostile. Each menstrual cycle adds to the cumulative damage.

This mechanism explains a clinical pattern that the standard model does not predict well. Patients with endometriosis tend to have progressively worse disease over time even with hormonal suppression. The progression is not just continued seeding from retrograde menstruation. It is the cumulative tissue damage from iron-driven oxidative chemistry in the pelvic environment. Excising the visible lesions does not reverse the damage to the surrounding tissue.

Iron handling is also dysregulated systemically in many endometriosis patients. Some have iron deficiency from chronic blood loss. Some have ferritin elevation as an acute-phase response to chronic inflammation. The systemic iron status often gives misleading readings on standard labs, which is why the iron picture in endometriosis benefits from interpretation through the lens of the broader inflammatory state.

Why surgery addresses the lesion but not the substrate

Excision surgery, performed by a skilled specialist, achieves a specific clinical goal. It removes the macroscopically visible endometriotic tissue. The procedure is necessary in many cases and provides meaningful relief in many. It addresses the lesion.

It does not address the five mechanisms described above. The elevated beta-glucuronidase activity continues. The gut barrier failure continues. The LPS-driven systemic inflammation continues. The mast cell-permissive microenvironment continues. The mitochondrial dysfunction continues. The iron-driven oxidative damage continues with each subsequent menstrual cycle. The substrate that selected for the original disease is fully intact after surgery.

This is why recurrence is so common. The body is producing the same physiological state that produced the original disease. Retrograde menstruation continues to seed cells into the peritoneum. The peritoneal environment is the same one that supported lesion development the first time. The result is the same. Lesions reestablish. Often in new locations because the previously affected sites are scarred and less receptive, but the disease itself persists at the systemic level.

The implication is not that surgery is the wrong choice. For many patients, surgery is necessary to relieve acute symptoms or to address specific complications (deep infiltrating endometriosis, endometriomas, fertility-limiting disease). The implication is that surgery alone is insufficient. Surgery plus addressing the upstream substrate produces a meaningfully different long-term outcome than surgery alone.

Why hormonal suppression addresses one source but not all

Continuous oral contraceptives, GnRH agonists, progestins, and aromatase inhibitors all reduce the estrogen exposure that endometriotic lesions experience. They reduce ovarian estrogen production directly. They reduce or eliminate menstrual cycling. They produce real symptomatic benefit in many patients.

They do not address the estrogen recirculated from the gut estrobolome. They do not address the systemic inflammation driving lesion-permissive immunology. They do not address the mast cell infiltration of pelvic tissues. They do not address the mitochondrial dysfunction in endometriotic tissue. They suppress one part of the system while the other parts continue to operate.

This explains the partial response patterns. Patients on hormonal suppression often experience meaningful but incomplete relief. The pain reduces but does not resolve. The disease persists at the tissue level even when symptoms improve. Discontinuation of the medication is followed by rapid recurrence in most cases. The medication was containment, not treatment of the underlying state.

The side effect profile of hormonal suppression is also relevant. GnRH agonists produce a chemically induced menopause with significant bone density, mood, and metabolic consequences. Long-term progestin use carries cardiovascular and breast cancer risks. Aromatase inhibitors are similar. The risk-benefit calculation for long-term hormonal suppression is patient-specific and not the focus of this article. The point is that even when the medication is tolerated, it does not produce the cure that its mechanism would suggest, because the mechanism it addresses is incomplete.

The clinical signature that suggests the framework applies

The endometriosis cases that benefit most from a Host Capacity Model approach share specific features. These features identify the cases where the upstream gut-bioenergetic mechanism is dominant. They include:

  • A history of significant gastrointestinal symptoms preceding or accompanying the endometriosis. Bloating, food sensitivities, IBS-pattern bowel changes, postprandial fatigue.
  • Concurrent or sequential SIBO, particularly recurrent SIBO that responds incompletely to standard treatment.
  • MCAS-spectrum symptoms: flushing, food reactions, environmental sensitivities, perimenstrual symptom flares.
  • Fatigue that is disproportionate to the visible pelvic disease.
  • Brain fog that worsens with cycle changes.
  • A history of significant antibiotic exposure preceding the onset of severe periods.
  • Family history of estrogen-related conditions (endometriosis, fibroids, breast cancer, ovarian conditions).
  • Response to dietary interventions that is more substantial than the disease severity would predict.
  • Worsening of disease in perimenopause despite the expected decline in estrogen, suggesting that local mechanisms beyond ovarian estrogen are dominant.

A patient who has most or all of these features is a case where the framework is likely to add value. A patient with none of them may have endometriosis driven by different upstream factors (genetic, immunologic, or developmental), in which case the framework's application is more limited.

What restoration looks like

A treatment approach anchored in the Host Capacity Model framework looks substantially different from standard endometriosis care. The conventional management remains appropriate where indicated: surgical excision when needed, hormonal suppression as the patient and her gynecologist decide, pain management. The upstream work proceeds in parallel.

The sequence:

First, identify the dominant upstream drivers in the specific patient. Through systematic case review, determine whether the estrobolome activity is the dominant driver, the LPS-driven systemic inflammation, the mast cell mechanism, the mitochondrial dysfunction, the iron handling, or some combination. Most cases involve multiple drivers; one is usually dominant.

Second, address the gut substrate that produces the elevated beta-glucuronidase activity. This includes addressing any underlying SIBO (per the framework in the recurrent SIBO article), reducing the dysbiotic taxa that produce excess beta-glucuronidase, supporting the recolonization of the obligate anaerobic core that supports healthy mucosal function, and reducing the inflammatory drivers that produced the dysbiosis in the first place.

Third, restore the regulatory cofactor pool. NAD+ precursor supplementation addresses the CD38-driven NAD+ depletion. Attention to methylation cofactors and B-vitamin status. Iron status interpreted through the lens of the broader inflammatory state, not just the standard ferritin reading.

Fourth, address the mast cell layer. The four-pattern MCAS framework applied locally to the pelvic environment and systemically. Cromolyn or comparable mucosal mast cell stabilization. Quercetin. Attention to histamine-rich foods if histamine intolerance is contributing.

Fifth, support the mitochondrial layer. CoQ10 (ubiquinol form), magnesium, B-vitamins in their methylated forms, and the broader mitochondrial cofactor support. This addresses both the systemic fatigue and contributes to the local tissue mitochondrial state.

Sixth, manage symptoms with containment as the upstream work proceeds. The hormonal therapy continues where it has been started, with reassessment over months as the upstream work shifts the picture. Pain management continues. Symptomatic care is not in conflict with mechanistic care.

The full sequence operates on the timescale of six to twelve months for substantial mechanistic improvement. The clinical symptom response may be faster, particularly as the upstream work reduces the systemic inflammation that was amplifying the pelvic pain. Many patients experience their first sustained improvement in pain severity and cycle predictability within three to six months. The full reorganization of the gut-estrobolome environment is slower and the durability of improvement increases over the following year.

This is the approach a Biomelogic consultation works through

The deliverable is a written mechanistic analysis that places the endometriosis case in HCM terms, identifies the dominant upstream drivers in the specific patient, and recommends sequencing for the patient's existing clinical team to implement alongside the conventional gynecological care. Biomelogic does not prescribe, does not modify hormonal therapy, and does not replace the gynecologist or excision specialist managing the case. The work is educational systems-biology analysis delivered in coordination with the medical team. Endometriosis is a disease that requires ongoing specialist medical care and the framework operates alongside that care, not as a substitute.

Frequently asked questions about endometriosis recurrence and the gut-endometriosis connection

Is endometriosis curable?

Cure is not the right framing. The clinically useful framing is durable remission, where the disease is quiescent, the symptoms are manageable, and progression is halted or substantially slowed. Bioenergetic and estrobolome restoration extends the durability of remission and reduces the rate of recurrence. The underlying genetic susceptibility, where present, is not eliminated by any current approach.

Can I avoid surgery if I do the upstream work?

This is a decision made with your gynecologist and excision specialist, not with Biomelogic. The Host Capacity Model framework is not a strategy for avoiding indicated surgery. Some patients with mild disease and predominant gut-driven mechanisms experience symptom improvement substantial enough that surgery is deferred or avoided. Other patients have anatomical disease (deep infiltrating endometriosis, endometriomas, structural issues) that requires surgical intervention regardless of upstream work. The surgical decision is medical care and belongs with the medical team.

Does the framework apply to all stages of endometriosis?

The framework is most directly applicable to cases dominated by inflammatory, hormonal, and bioenergetic drivers. Mild and moderate disease, recurrent disease after surgery, and disease with prominent systemic features (fatigue, gut symptoms, MCAS overlap) are the strongest fits. Severe deep infiltrating endometriosis and structural disease still benefits from the framework as adjunct care, but the surgical and conventional gynecological management remains primary.

Should I take a probiotic for endometriosis?

Probiotic recommendations in endometriosis are individualized. Some probiotics (specifically Lactobacillus crispatus and related strains that produce lactic acid) may shift the urogenital microbiome favorably. Some probiotics (particularly some Bacteroides species included in broad-spectrum probiotics) may increase beta-glucuronidase activity and worsen the estrobolome picture. The specific probiotic and the patient's specific baseline microbial state both matter. A blanket recommendation is not appropriate.

What about calcium-D-glucarate for endometriosis?

Calcium-D-glucarate is a beta-glucuronidase inhibitor that has been studied for various estrogen-related conditions. It is a reasonable adjunct in some endometriosis cases where the estrobolome mechanism is dominant. The evidence base is limited but the mechanistic rationale is direct. The decision to use it is between the patient and her clinical team.

Why does my endometriosis get worse in perimenopause when estrogen should be falling?

This is a counter-intuitive but well-documented pattern. The explanation involves several factors: the falling estrogen is accompanied by falling progesterone, often disproportionately, producing relative estrogen dominance; the local lesion aromatase activity becomes more important relative to ovarian estrogen production; and the broader inflammatory and bioenergetic state often deteriorates in perimenopause, supporting lesion activity.

Is Mohammed Attallah a doctor?

No. Mohammed Attallah is an independent systems-biology researcher and developer of the Host Capacity Model. He is not a licensed clinician. Biomelogic provides educational systems-biology analysis that operates alongside the client's existing licensed medical team, particularly the gynecologist or excision specialist managing the endometriosis. Endometriosis requires ongoing specialist medical care and the framework does not replace that care.

Do you work with endometriosis specifically?

Yes. Endometriosis cases are a substantial part of the practice, particularly cases with concurrent SIBO, MCAS overlap, or perimenopause-driven worsening. The framework is particularly useful for patients who have had at least one surgery, who are interested in understanding the upstream mechanism, and who have an established gynecology relationship to coordinate the work with.

What does a Biomelogic consultation cost?

The Standard Consultation is $650 one time, which includes the case review, the live session, and the written mechanistic analysis. The full service menu is at biomelogic.net/services. HSA and FSA eligibility varies.

How do I get started?

The lowest-friction starting point is the free 15-minute discovery call. The call determines whether the case is a fit. If yes, the next step is the Standard Consultation.

Working with Biomelogic on endometriosis

If the patterns described above resonate with the endometriosis case you have been navigating, a Biomelogic consultation may be useful. The work is appropriate for patients with an established gynecology relationship, who are interested in understanding the mechanistic layer that conventional endometriosis care does not address, and who are willing to do the slow upstream work alongside the medical management.

The lowest-friction starting point is the free 15-minute discovery call. The call is not medical advice and not a sales pitch. It exists to determine whether the framework is appropriate for the case.

For patients ready to proceed directly to a full case workup, the Gate 1 intake form is the starting point.

For readers wanting the deeper framework, The Host Capacity Model is the canonical framework page.

Related articles

Selected primary research

The mechanisms described in this article are drawn from primary research published over the past two decades. Key references include:

  • Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe. 2011;10(4):324-335.
  • Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: Physiological and clinical implications. Maturitas. 2017;103:45-53.
  • Khan KN, Kitajima M, Hiraki K, et al. Toll-like receptors in innate immunity: role of bacterial endotoxin and toll-like receptor 4 in endometrium and endometriosis. Gynecol Obstet Invest. 2009;68(1):40-52.
  • Ata B, Yildiz S, Turkgeldi E, et al. The endobiota study: comparison of vaginal, cervical and gut microbiota between women with stage 3/4 endometriosis and healthy controls. Sci Rep. 2019;9(1):2204.
  • Salliss ME, Farland LV, Mahnert ND, Herbst-Kralovetz MM. The role of gut and genital microbiota and the estrobolome in endometriosis, infertility and chronic pelvic pain. Hum Reprod Update. 2021;28(1):92-131.
  • Leonardi M, Hicks C, El-Assaad F, et al. Endometriosis and the microbiome: a systematic review. BJOG. 2020;127(2):239-249.

These references are starting points. The endometriosis-microbiome literature has expanded substantially in the past five years. The framework described in this article synthesizes findings across this literature into a clinical interpretation that has not yet been formalized in mainstream gynecology.